OA10.06 a First-In-Human Phase 1 Trial of the EGFR-cMET Bispecific Antibody JNJ-61186372 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.292
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

P1.01-47 Phase I/Ii Trial of Dasatinib and Osimertinib in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

A Phase I Trial of Temsirolimus and Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer

Chemotherapy
MedicineDrug DiscoveryInfectious DiseasesOncologyPharmacology
2016English

A Phase II Trial of Erlotinib Monotherapy for Pretreated Elderly Patients With Advanced EGFR Wild-Type Non-Small Cell Lung Cancer

BMC Research Notes
BiochemistryMedicineGeneticsMolecular Biology
2015English

140PD: LUX-Lung 7: A Phase IIb, Global, Randomised, Open-Label Trial of Afatinib vs Gefitinib as First-Line Treatment for Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC) Harbouring Activating EGFR Mutations

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2016English

Phase II Trial of Gefitinib in Combination With Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer With Activating EGFR Gene Mutations: The Okayama Lung Cancer Study Group Trial 1001

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2015English

TG4010 Immunotherapy Combined With First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC): Phase IIb Results of the TIME Study

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2014English

Randomized Phase II Trial of Seribantumab in Combination With Erlotinib in Patients With EGFR Wild‐Type Non‐Small Cell Lung Cancer

Oncologist
Cancer ResearchMedicineOncology
2019English

Cost-Effectiveness of First-Line Therapy for Advanced Non-Small Cell Lung Cancer (Nsclc)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

P1.01-109 Phase I Study of Apatinib Plus Gefitinib as First-Line Therapy in Patients With EGFR Mutant Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy